Viewing nowCombinationZabiam 50/850 mg (Sitagliptin Hydrate, Metformin Hydrochloride)
Metformin Hydrochloride 850mg · Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication · Combination
Unimed Pharmaceutical Co., Ltd.

MFDS item code 202302024 · Approved 2023.06.30 · Insurance code 649508360
Improves blood glucose control in patients with type 2 diabetes mellitus
This medication is developed to assist patients with type 2 diabetes in controlling their blood sugar levels. When taken in conjunction with dietary and exercise therapy, it can effectively manage blood sugar levels. Sitagliptin and Metformin work together to help stabilize blood sugar levels. This offers better blood sugar management even for those who struggle with blood sugar control. This medication is used for improving blood sugar control in type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. Generally, take this medicine twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: For patients with inadequate glycemic control on metformin monotherapy, the recommended initial dose is the current metformin dose together with sitagliptin 50 mg twice daily (total daily dose 100 mg). Patients switching from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial metformin dose should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that could increase the risk of lactic acidosis, with the following dose adjustment. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
This medication is used for the treatment of diabetes and helps in managing blood sugar levels. During usage, severe allergic reactions may occur; if symptoms such as skin rash or difficulty breathing emerge, discontinue use immediately and consult a doctor. Additionally, there is a risk of pancreatitis (inflammation of the pancreas), so if you experience abdominal pain, vomiting, or persistent abdominal discomfort, inform your healthcare provider promptly. This medication contains ingredients that can affect kidney function, and patients with severely impaired kidney function should not take it. In particular, avoid using this medication in cases of dehydration, severe infection, or sudden worsening of heart function, and discontinue use for a period before and after surgery. Women who are pregnant or breastfeeding should refrain from using this medication for safety. During the use of this medication, regular blood tests and kidney function tests should be conducted to monitor your health status. Moreover, when used in conjunction with other blood sugar lowering agents, hypoglycemia symptoms may occur, so it is important to be cautious and respond immediately if symptoms appear. Alcohol consumption may pose risks when taken with this medication, so it is advisable to avoid alcohol during treatment. When performing tasks requiring attention, such as driving or operating machinery, be cautious for hypoglycemia or dizziness. Rarely, severe joint pain or skin conditions may occur; if these symptoms develop, inform your doctor. During treatment, maintaining a healthy diet and regular exercise, along with regularly checking blood sugar and kidney function, is important.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent air exposure, and it is recommended to keep it at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the efficacy and safety of the medication.
Pink oval film-coated tablet
60 tablets/box [10 T/PTP*6]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 850mg · Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication · Combination
Unimed Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.